Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
10 févr. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
10 janv. 2022 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February – – Five Pivotal Clinical Trials are Planned and Ongoing in...
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
22 déc. 2021 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
13 déc. 2021 18h15 HE
|
Agios Pharmaceuticals, Inc.
– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency Patients – –...
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
13 déc. 2021 10h30 HE
|
Agios Pharmaceuticals, Inc.
– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated – – Agios to Host Investor Webcast on Dec. 14,...
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
13 déc. 2021 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients – – Safety Profile Consistent with Previously Reported Clinical Data – – Agios Announces Initiation of...
Agios Appoints Richa Poddar as Chief Commercial Officer
15 nov. 2021 16h01 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition
04 nov. 2021 09h00 HE
|
Agios Pharmaceuticals, Inc.
– Extension Data for Mitapivat in PK Deficiency and Thalassemia Demonstrate Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis – – New Data from Two Investigator...
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
03 nov. 2021 07h11 HE
|
Agios Pharmaceuticals, Inc.
– Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022 – – Initiated ENERGIZE and ENERGIZE-T Phase 3 Studies...
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
21 oct. 2021 16h01 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...